
RASP
Healthcare · Biotechnology · $385,905 market cap
$0.00050.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 20, 2024 | Before the open | — | -0.00 | — |
| Jun 30, 2021 | Time not confirmed | — | -0.00 | — |
| Mar 31, 2021 | Time not confirmed | — | -0.00 | — |
| Dec 31, 2020 | Time not confirmed | — | -0.00 | — |
| Sep 30, 2020 | Time not confirmed | — | -0.03 | — |
| Jun 30, 2020 | Time not confirmed | — | -0.04 | — |
| Mar 31, 2020 | Time not confirmed | — | -0.00 | — |
| Dec 31, 2019 | Time not confirmed | — | -0.00 | — |
| Sep 30, 2019 | Time not confirmed | — | -0.00 | — |
| Jun 30, 2019 | Time not confirmed | — | -0.00 | — |
| Mar 31, 2019 | Time not confirmed | — | -0.00 | — |
| Dec 31, 2018 | Time not confirmed | — | -0.01 | — |
| Sep 30, 2018 | Time not confirmed | — | -0.01 | — |
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301.…
| Time not confirmed |
| — |
| -0.01 |
| — |
| Mar 31, 2018 | Time not confirmed | — | -0.02 | — |